Citron Research: Questcor in Cover-Up Mode

0
Citron Research: Questcor in Cover-Up Mode

Over the coming months, Citron Research will release a series of articles on Questcor Pharmaceuticals Inc (NASDAQ:QCOR) intended to shed light on probable issues of interest to the multi-pronged investigation underway by multiple regulatory agencies into numerous aspects of Questcor’s business strategy that political correct-speak would deem “legally challenged”.  These articles will dig deeper into topics such as:

Play Quizzes 4
  • The Chronic Disease Fund, and the role it plays in contributing to Questcor Pharmaceuticals Inc (NASDAQ:QCOR)’s revenues
  • Medicare billing (it is very dangerous to participate in a scheme to defraud the Federal Government)
  • Insurance reimbursement coding for Acthar

Meanwhile, today’s question is whether Questcor Pharmaceuticals Inc (NASDAQ:QCOR)’s Synacthen acquisition is anti-competitive.  The points raised in Citron’s article last week are relevant to the FTC’s inquiry, demonstrating Questcor’s intent to suppress competition by acquiring Synacthen is exposed by their own sell-side analysts.

We are sure that Questcor Pharmaceuticals Inc (NASDAQ:QCOR) will now try to posture to the FTC that Synacthen is a completely different drug, arguing that while it has similarities, it cannot be regarded as a replacement for HP Acthar Gel.  This piece of evidence presented below is for the FTC, so shareholders please cover your eyes.

Fund Manager Profile: Zhang Hui Of China’s Southern Asset Management

investHistorically, the Chinese market has been relatively isolated from international investors, but much is changing there now, making China virtually impossible for the diversified investor to ignore. Earlier this year, CNBC pointed to signs that Chinese regulators may start easing up on their scrutiny of companies after months of clamping down on tech firms. That Read More

See full PDF here.

Questcor Update Final by ValueWalk.com

Updated on

Sheeraz is our COO (Chief - Operations), his primary duty is curating and editing of ValueWalk. He is main reason behind the rapid growth of the business. Sheeraz previously ran a taxation firm. He is an expert in technology, he has over 5.5 years of design, development and roll-out experience for SEO and SEM. - Email: sraza(at)www.valuewalk.com
Previous article Apple iPhone 5S, 5C Preorders On China Mobile Removed
Next article Monster Beverage Corporation (MNST) Reacts to Study on Energy Drinks

No posts to display